Hemoglobinopathies

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

A Long-term Follow-up Study in Participants Who Received CTX001

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Allo HSCT for High Risk Hemoglobinopathies

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

A Blood Stem Cell Transplant for Sickle Cell Disease

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, Bangladesh

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Discarded Bone Marrow for Hematology Research

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Prevalence of Hemoglobinopathies Associated With Significant Hb Variants in the Chattogram Region of Bangladesh

Prevalence and Hematological Characteristics of Hemoglobinopathies

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)